On May 18, the ATS 2025 International Conference grandly commenced in San Francisco, California, USA. ChioceMMed showcased multiple innovative respiratory health products, focusing on scenarios such as respiratory chronic disease management, SpO2 monitoring and sleep medicine. The company presented its self-developed intelligent solutions to the international academic community, demonstrating China’s cutting-edge medical technology in the field.

As one of the most influential academic and technological showcase platforms in global respiratory medicine, this year’s ATS International Conference has attracted over 10,000 respiratory physicians, researchers, and industry leaders from around the globe. Participants collaboratively explore the latest breakthroughs in pulmonary diseases, critical care, and sleep medicine. ChioceMMed has highlighted a range of products tailored for specific respiratory care scenarios, including oxygen therapy and respiratory rehabilitation training for COPD patients, asthma management for children, and screening for sleep apnea. By leveraging intelligent interconnected technology, ChioceMMed has built an innovative product ecosystem that integrates data-driven monitoring, real-time anomaly alerts, and cross-platform remote collaboration. This digital closed-loop system aims to deliver precision-driven, full-cycle smart management solutions for diverse respiratory disease populations, fostering a holistic healthcare environment for long-term patient care.

On the first day of the conference, ChioceMMed’s booth became the center of attention. Respiratory specialists, representatives from healthcare institutions, and industry partners from across Europe and America gathered to engage in in-depth discussions about technical details and potential collaboration opportunities. 

Under the strategic guidance of Tianjin Chasesun Pharmaceutical Co., Ltd., ChoiceMMed will lead with marketing initiatives to drive high-quality enterprise development, continuously deepen the research and development of core technologies in the respiratory health field, accelerate the clinical translation process of innovative respiratory health products, further expand the application ecosystem in home and community healthcare settings, and build a more efficient chronic disease health management system.